Spots Global Cancer Trial Database for Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Official Title: Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Study ID: NCT04684147
Interventions
Study Description
Brief Summary: The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.
Detailed Description: The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia. The study consists of screening period (8 weeks), treatment period (4 weeks), and follow-up period (2 years at most).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Boren Hospital, Beijing, Beijing, China
Xinqiao Hospital of TMMU, Chongqing, Chongqing, China
Nanfang Hospital, Guangzhou, Guangdong, China
Yanda hospital, Hebei medical university, Sanhe, Hebei, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
The affiliated hospital of Xuzhou medical university, Xuzhou, Jiangsu, China
Tongji Hospital of Tongji University, Shanghai, Shanghai, China
West China Hospital，Sichuan University, Chengdu, Sichuan, China
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
The First Affiliated Hospital, Zhejiang University school of Medicine, Hangzhou, Zhejiang, China
Contact Details
Name: Jianxiang Wang, Dr.
Affiliation: Institute of Hematology & Blood Diseases Hospital, China
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
